Pipecuronium

DB01338ApprovedInvestigationalWithdrawnSmall molecule

Pipecuronium is a nondepolarizing neuromuscular blocking agent used to relax muscles during anesthesia and surgical procedures. Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

Mechanism: Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.
Curator reviewed
Primary indication: Used as a muscle relaxant during anesthesia and surgical procedures.Curator reviewed
Formula / weight: C₃₅H₆₂N₄O₄ · 602.8912 g/mol (avg)
First approval: United States, 1990
Also known as: Pipecurium

Resolves to

Compound

UNII1N3O74HM92CAS68399-58-6ChEMBLCHEMBL1201206ChEBI8230PubChem50192KEGGC07554

Clinical / RWD

RxNorm33742ATCM03AC06PharmGKBPA164764567

Structure

InChIKeyOWWLUIWOFHMHOQ-XGHATYIMSA-NSMILES

[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1

Targets

Q15822CHRNA2P08172CHRM2P20309CHRM3

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,270Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

1Marketed productAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 16 drug categories

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pipecuronium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account